Background Gemcitabine plus cisplatin is a standard treatment for stages ⅢB and Ⅳ nonsmall cell lung cancer (NSCLC). This randomized phase Ⅱ study evaluated
Background Recent studies have suggested that susceptibility to major depressive disorder (MDD) might be related to the serotonin 1A receptor (5-HTR1A) C(-1019)